InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,308.56
(
0.01%
)
US TECH 100
18,183.96
(
-0.07%
)
Dow Jones
39,820.23
(
0.03%
)
Brent Oil
82.71
(
-0.99%
)
Bitcoin
69,664.47
(
-2.50%
)
Post# of 251872
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119666
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197623

Wednesday, 12/02/2015 9:42:00 AM

Wednesday, December 02, 2015 9:42:00 AM

Post# of 251872
ABBV/ENTA—FDA accepts NDA for qD formulation of V-Pak for review:

http://finance.yahoo.com/news/abbvie-announces-fda-acceptance-drug-130000460.html

The difference between the qD formulation of V-Pak and regular V-Pak is that the qD formulation includes an extended-release version of dasabuvir (a/k/a ABT-333, the non-nucleoside polymerase inhibitor).

The PDUFA date for this NDA should be on or about 10/2/16.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up